Page 4 - சமீப வணிக சிறப்பம்சங்கள் News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from சமீப வணிக சிறப்பம்சங்கள். Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In சமீப வணிக சிறப்பம்சங்கள் Today - Breaking & Trending Today

CryoLife Reports First Quarter 2021 Financial Results

CryoLife Reports First Quarter 2021 Financial Results
yahoo.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from yahoo.com Daily Mail and Mail on Sunday newspapers.

United States , D Ashley Lee , Pat Mackin , Brian Johnston Lynn Lewis , Exchange Commission , Gilmartin Group , Ascyrus Medical , Cryolife Inc , First Quarter , Recent Business Highlights , Chief Executive , Conference Call , Investor Relations , Private Securities Litigation Reform Act , Consolidated Statements , Consolidated Statement , Diluted Income , Per Common , Senior Convertible , Vice President , Chief Financial Officer , Lynn Lewis , ஒன்றுபட்டது மாநிலங்களில் , ட ஆஷ்லே லீ , பேட் மேக்கின் , பிரையன் ஜான்ஸ்டன் லின் லெவிஸ் ,

Opera Limited announces first quarter 2021 financial results, exceeds expectations for revenue growth and adjusted EBITDA

Opera Limited announces first quarter 2021 financial results, exceeds expectations for revenue growth and adjusted EBITDA
prnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prnewswire.com Daily Mail and Mail on Sunday newspapers.

United States , Hong Kong , Song Lin , United Kingdom , Frode Jacobsen , Exchange Commission , Prnewswire Opera Limited , Months Ended March , Opera News , Recent Business Highlights , Eastern Time , European Time , Securities Litigation Reform Act , Opera Limited , ஒன்றுபட்டது மாநிலங்களில் , ஹாங் காங் , பாடல் லின் , ஒன்றுபட்டது கிஂக்டம் , பரிமாற்றம் தரகு , ஓபரா செய்தி , சமீப வணிக சிறப்பம்சங்கள் , கிழக்கு நேரம் , ஐரோப்பிய நேரம் , பத்திரங்கள் வழக்கு சீர்திருத்தம் நாடகம் , ஓபரா வரையறுக்கப்பட்டவை ,

KalVista Pharmaceuticals, Inc.: KalVista Pharmaceuticals Reports Third Fiscal Quarter Results

KalVista Pharmaceuticals, Inc.: KalVista Pharmaceuticals Reports Third Fiscal Quarter Results
- IND Submitted for Oral Prophylactic HAE Treatment Candidate KVD824; Phase 2 Expected to Initiate in Q2 2021 -
- Following Upsized Public Offering, Funded to KVD900 NDA Filing -
KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of small molecule protease inhibitors, today provided an operational update and released financial results for the third fiscal quarter ended January 31, 2021.
We are making excellent progress in our commitment to providing those with hereditary angioedema a complete set of oral options to manage their disease. The data announced last month for KVD900 as an oral on-demand therapy were overwhelmingly positive and show that patients don t have to compromise on efficacy or rely on injectables. We view this data as validation of our work in oral plasma k ....

Leah Monteiro , Andrew Crockett , Exchange Commission , Kalvista Pharmaceuticals Inc , Corporate Communications Investor Relations , Trial Results Statistically , Clinically Significant , Oral Prophylactic , Upsized Public Offering , Vista Pharmaceuticals , Chief Executive Officer , Fiscal Quarter , Recent Business Highlights , Third Fiscal Quarter Financial Results , Merck Option Agreement , Kalvista Pharmaceuticals , Securities Litigation Reform Act , Consolidated Statement , Consolidated Statements , லியா மான்டீரோ , ஆண்ட்ரூ குரோக்கெட் , பரிமாற்றம் தரகு , பெருநிறுவன தகவல்தொடர்புகள் முதலீட்டாளர் உறவுகள் , மருத்துவ ரீதியாக குறிப்பிடத்தக்க , மேம்பட்டது பொது பிரசாதம் , விஸ்டா மருந்துகள் ,

3D Systems Reports Fourth Quarter and Full Year 2020 Financial Results (Unaudited), Reschedules Form 10-K Filing

(1) See Appendix for reconciliation of GAAP and non-GAAP operating income (loss), net income (loss) and basic and diluted income (loss) per share.
Summary Comments
Commenting on the company’s progress in 2020, Dr. Graves said, “With our singular focus on additive manufacturing, we were pleased to deliver strong growth at the end of what was an unprecedented year. The execution of our four-stage plan to deliver increased value to our customers and shareholders, initiated in the summer of 2020, took hold and rapidly gained momentum as we moved through the second half of the year. By the fourth quarter, the results of these efforts in our two focused businesses became very clear. Our Healthcare business delivered exceptional revenue growth of 48% year-over-year, driven strongly by both dental and medical applications, while also making a significant technological breakthrough in our emerging regenerative medicine area, which will be increasingly important to our He ....

Exchange Commission , Aerospace Defense , D Systems Inc , D Systems Corporation , Systems Corporation , Annual Report , Late Filing , Jeff Graves , Quarter Financial , Operational Results , Recent Business Highlights , Ended December , Fourth Quarter Results , Profit Margin , Private Securities Litigation Reform Act , Diluted Income , Additive Manufacturing , Condensed Consolidated Statements , Year Ended December , Nyse Ddd , 3d Systems Inc , பரிமாற்றம் தரகு , விண்வெளி பாதுகாப்பு , ட அமைப்புகள் இன்க் , ட அமைப்புகள் நிறுவனம் , அமைப்புகள் நிறுவனம் ,

Urovant Sciences Provides Merger Update and Reports Third Quarter Fiscal Year 2020 Results

Urovant Sciences Provides Merger Update and Reports Third Quarter Fiscal Year 2020 Results
SEC reviewing preliminary proxy statement for the previously announced merger of the Company with Sumitovant Biopharma
Special General Meeting of Shareholders to approve the merger is expected to occur by the end of 1Q CY2021
U.S. commercial launch of GEMTESA (vibegron) to treat OAB is on track for late-Q1 CY2021, following U.S. FDA approval in December 2020
Urovant Sciences (Nasdaq: UROV)
today reported financial results for its fiscal quarter ended December 31, 2020.
The third quarter of fiscal 2020 was transformational for Urovant. In November, we announced the signing of a definitive merger agreement with Sumitovant Biopharma, the majority shareholder of Urovant. Under the terms of the definitive agreement, Urovant will be acquire by Sumitovant Biopharma at a 96% premium to the closing price of our shares prior to the agreement being announced. We look forward t ....

New York , United States , City Of , United Kingdom , Sumitomo Dainippon Pharma , Sumitovant Biopharma , Ryan Kubota , James Robinson , Dainippon Pharmaceutical Co Ltd , Urovant Sciences Nasdaq , Urovant Investor Relations Department , Spirovant Sciences , European Union , Due To Sunovion Pharmaceuticals Inc , Urovant Sciences , Drug Administration , Myovant Sciences , Ion Channel Innovations , Merck Sharp Dohme Corp , Altavant Sciences , Exchange Commission , Due To Roivant Sciences Ltd , Sumitomo Dainippon Pharma Co Ltd , Sumitomo Pharmaceuticals Co Ltd , Sumitovant Biopharma Ltd , General Meeting ,